Navigation Links
Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
Date:12/20/2007

/p>

In recent months, Peregrine has implemented a number of initiatives to accelerate its three lead clinical programs.

Bavituximab Solid Tumor Clinical Program

In support of the Phase II bavituximab cancer program, Peregrine filed protocols for two breast cancer combination therapy trials and has already received regulatory approval to proceed with one of those protocols, which is assessing bavituximab in combination with docetaxel in patients with breast cancer. Patient enrollment in this trial is expected to begin in early 2008. Regulatory approval for the second breast cancer trial and for a previously filed combination therapy trial in patients with non-small cell lung cancer is expected early in 2008. The company also is taking action to accelerate its Phase I bavituximab cancer trial in the U.S., with the goal of laying the foundation for U.S. Phase II studies. Peregrine recently added a new study site in Charlotte, North Carolina, and a total of five clinical sites are now screening and recruiting patients for this study. Peregrine expects to complete the Phase I trial during 2008. The bavituximab cancer clinical program will be discussed at an important scientific forum when interim clinical data is presented in February 2008 at the 10th Annual International Symposium on Anti-Angiogenic Agents (Angio 2008).

Bavituximab Hepatitis C Virus (HCV) Clinical Program

The company's trial of bavituximab in HCV patients co-infected with HIV began enrolling and dosing patients, and with the addition of new clinical sites at The Johns Hopkins Hospital and a private clinic in Orange County, California, a total of three clinical sites are now screening and recruiting patients in this innovative study. The bavituximab HCV clinical program was awarded an oral presentation slot for the second year in a row at the prestigious Annual Meeting of the American Association for the Study of Liver Disease held last November. Final results from the Phase
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... NYHeat drives classical phase transitionsthink solid, liquid, ... when the temperature drops. If phase transitions ... quantum mechanics reigns, subtle fluctuations can dramatically ... the U.S. Department of Energy,s Brookhaven National ... this frigid landscape of absolute zero to ...
(Date:9/15/2014)... Calif. , Sept. 15, 2014  FlexTech ... (RFP) for flexible, printed product demonstrators (demos) and ... two-stage RFP process with pre-proposals due on October ... 2015.  Funds for proposals ultimately selected are provided ... have a significant cost share by the proposing ...
(Date:9/15/2014)... led by Northeastern University has developed a novel ... a variety of nanocarbon structures in carbon nanotube ... which will allow the researchers to tailor the ... applications ranging from electronic devices to CNT-reinforced composite ... equipment. , Their findings were published in the ...
(Date:9/15/2014)... Research and Markets has announced the addition of the ... Technology, by Application - Global Forecast to 2018" report ... is next-generation technology used for strategically sequencing the coding region ... the total of all exons of an organism, represents only ... proteins after translation. It is responsible for the occurrence of ...
Breaking Biology Technology:Elusive quantum transformations found near absolute zero 2Elusive quantum transformations found near absolute zero 3FlexTech Alliance Issues 2015 Request for Proposals in Flexible, Printed Electronics 2Northeastern University Researchers Develop Novel Method for Working with Nanotubes 2Global Whole Exome Sequencing (Systems, Kits, Library Preparation, Target Enrichment) Market by Product, by Services, by Technology, by Application - Forecast to 2018 2Global Whole Exome Sequencing (Systems, Kits, Library Preparation, Target Enrichment) Market by Product, by Services, by Technology, by Application - Forecast to 2018 3
... N.J., Jan. 7 Par Pharmaceutical Companies, Inc. (NYSE: ... Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, at ... The audio-only live webcast will be accessible through the J.P. ... the Par website at www.parpharm.com . A replay ...
... Technology Index Shows Stronger Performance in Turbulent EconomyOAKBROOK TERRACE, ... trade association representing all segments of the high-tech industry, ... Index (Nasdaq: ILTI ) outperformed the Dow ... Index(R) (COMP) since its inception in 2008.On May 19, ...
... and Efficient Cold Chain VisibilityBEVERLY, Mass., Jan. 7 ... in cold-chain visibility solutions, has launched the TempTale(R)4USB ... latest model of the industry-leading TempTale4 product line ... without proprietary software or readers. Sensitech is a ...
Cached Biology Technology:NASDAQ OMX AeA Illinois Tech Index Outperforms Market 2NASDAQ OMX AeA Illinois Tech Index Outperforms Market 3Introducing Sensitech's TempTale(R)4USB Temperature Monitor 2Introducing Sensitech's TempTale(R)4USB Temperature Monitor 3
(Date:9/15/2014)... The creation of the Vuoksi River and the subsequent ... approximately 6,000 years ago revealed thousands of square kilometres ... research project organised by University of Helsinki researchers has ... has played in the interaction between nature and humans. ... the area underwent significant changes and gave rise to ...
(Date:9/15/2014)... Schizophrenia is generally considered to be a disorder ... both genetic and environmental, with other neurodevelopmental disorders such ... for brain development is determined by the combined effects ... range of environmental factors. , However, longitudinal brain imaging ... in order to map the disturbances in brain structures ...
(Date:9/15/2014)... , , , , , , , ... , , , , , , ... shows that schizophrenia isn,t a single disease but a group of eight genetically distinct disorders, each with its own set of symptoms. The finding could be ... , , , , , ... , , , , ...
Breaking Biology News(10 mins):The creation of the Vuoksi River preceded a significant cultural shift 2Brain Development in Schizophrenia Strays from the Normal Path 2Schizophrenia not a single disease but multiple genetically distinct disorders 2Schizophrenia not a single disease but multiple genetically distinct disorders 3Schizophrenia not a single disease but multiple genetically distinct disorders 4Schizophrenia not a single disease but multiple genetically distinct disorders 5
... to tackle the human impact on biodiversity require ... working with common goals and frameworks. This emerged ... Science Foundation (ESF), which moved towards establishing an ... biodiversity analysis on the back of existing initiatives. ...
... dating back to the journals of Henry David Thoreau, scientists ... Walden Pond have borne the effects of climate change in ... by global warming have included beloved species like lilies, orchids, ... in the Proceedings of the National Academy of Sciences ...
... release is available in French . ... $100,000 grant from the Gates Foundation to help establish ... "People are always asking why the pharmaceutical ... the poor, like parasitic infections," said Dr. Timothy Geary, ...
Cached Biology News:European biodiversity and ecosystem scientists merge and gear up for long-term research 2Effects of climate change vary greatly across plant families 2Boost from McGill, Gates Foundation helps Africans control pharma research 2
...
... is essential for hunting and analyzing ... such as EST sequencing projects, microarrays, ... kit is developed for normalization of ... intended for directional cloning. While most ...
Peptide-affinity Purified Polyclonal Antibody to ICEBERG Peptide with sequence EEDPQLASKMGLH, from C Terminus of the protein sequence according to NP_067546...
Purified anti-Fanconi anemia D2-Phosphorylated (Ser222)...
Biology Products: